Capecitabine-associated enterocolitis: Narrative literature review of a rare adverse event and a case presentation

References

• Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23–44.
   PubMed Web of Science ®Google Scholar
• Koukourakis GV, Kouloulias V, Koukourakis MJ, et al. Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review. Molecules. 2008;13(8):1897–1922.
   PubMed Web of Science ®Google Scholar
• Dean L. Capecitabine therapy and DPYD genotype. Medical Genetic Summaries. 2016. [E-pub]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK385155/
   Google Scholar
• Comella P. A review of the role of capecitabine in the treatment of colorectal cancer. Ther Clin Risk Manag. 2007;3(3):421–431.
   PubMedGoogle Scholar
• Summary of Product Characteristics- Xeloda (Capecitabine). Roche pharmaceuticals. [accessed 08 August 2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf [year of revision of the text 2015].
   Google Scholar
• Evidence Summary- Xeloda (Capecitabine). VA PBM Services. [accessed 08 August 2020]. Available from: www.pbm.va.gov [year of revision of the text 2014].
   Google Scholar
• Alexandrescu DT, Dutcher JP, Wiernik PH. Capecitabine-induced pancolitis. Int J Colorectal Dis. 2007;22(4):455.
   PubMed Web of Science ®Google Scholar
• Cetin B, Buyukberber S, Sentürk S, et al. Ischemic colitis after capecitabine plus cisplatin treatment in advanced gastric cancer. J Thromb Thrombolysis. 2011;31(4):503–506.
   PubMed Web of Science ®Google Scholar
• Gordon VL, Harding GA, Czaykowski P. Capecitabine-induced, nonneutropenic enterocolitis. J Gastrointest Cancer. 2011;42(4):278–281.
   PubMedGoogle Scholar
• Bouma G, Imholz AL. Ileitis following capecitabine use. Ned Tijdschr Geneeskd. 2011;155:A3064.
   PubMedGoogle Scholar
• Radwan R, Namelo WC, Robinson M, et al. Ileitis secondary to oral capecitabine treatment? Case Rep Med. 2012;2012:154981.
   PubMedGoogle Scholar
• Al-Gahmi AM, Kerr IG, Zekri JM, et al. Capecitabine-induced terminal ileitis. Ann Saudi Med. 2012;32(6):661–662.
   PubMed Web of Science ®Google Scholar
• Gurzu S, Jung I, Comsulea M, et al. Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman. Diagn Pathol. 2013;8:150.
   PubMed Web of Science ®Google Scholar
• Mokrim M, Aftimos PG, Errihani H, et al. Breast cancer, DPYD mutations and capecitabine-relate ileitis: description of two cases and a review of the literature. BMJ Case Rep. 2014;2014(1):bcr2014203647–bcr2014203647.
   PubMedGoogle Scholar
• Maggo G, Grover SC, Grin A. Capecitabine induced colitis. Pathol Res Pract. 2014;210:606–668.
   Google Scholar
• Soldini D, Gasper A, Montani M, et al. Apoptotic enteropathy caused by antimetabolites and TNF-α antagonists. J Clin Pathol. 2014;67(7):582–586.
   PubMed Web of Science ®Google Scholar
• Lee SF, Chiang CL, Lee AS, Wong FC, et al. Severe ileitis associated with capecitabine: two case reports and review of the literature. Mol Clin Oncol. 2015;3(6):1398–1400.
   PubMedGoogle Scholar
• Nicosia L, Russo I, De Sanctis V, et al. Two cases of capecitabine-induced ileitis in patients treated with radiochemotherapy to the pelvis and review of the literature. J Gastrointest Cancer. 2018;49(4):538–542.
   PubMed Web of Science ®Google Scholar
• van Hellemond IEG, Thijs AM, Creemers GJ. Capecitabine-associated terminal ileitis. Case Rep Oncol. 2018;11(3):654–659.
   PubMed Web of Science ®Google Scholar
• Khan T, Mujtaba M, Flores MS, et al. A case of pneumatosis intestinalis with pneumoperitoneum as a potential delayed adverse effect of capecitabine. World J Oncol. 2019;10(3):151–152.
   PubMedGoogle Scholar
• Pow-Anpongkul P, Chu PG, Kidambi TD. Capecitabine-induced enteritis leading to small bowel obstruction. Gastroenterology. 2019;156(5):e1–e9.
   Web of Science ®Google Scholar
• Dao AE, Hsu A, Nakshabandi A, et al. Role of colonoscopy in diagnosis of capecitabine associated ileitis: two case reports. World J Gastrointest Endosc. 2019;11(5):383–388.
   PubMed Web of Science ®Google Scholar
• Jensen SA, Sorensen JB. 5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity. Cancer Chemother Pharmacol. 2012;69(1):57–64.
   PubMed Web of Science ®Google Scholar
• Soares PM, Mota JM, Souza EP, et al. Inflammatory intestinal damage induced by 5-fluorouracil requires IL-4. Cytokine. 2013;61(1):46–49.
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
   PubMed Web of Science ®Google Scholar
• Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994;12(11):2248–2253.
   PubMed Web of Science ®Google Scholar
• Mattison LK, Fourie J, Desmond RA, et al. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with caucasians. Clin Cancer Res. 2006;12(18):5491–5495.
   PubMed Web of Science ®Google Scholar
• Johnson MR, Yan J, Shao L, et al. Semiautomated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl. 1997;696(2):183–191.
   PubMed Web of Science ®Google Scholar
• Van Staveren MC, Guchelaar HJ, van Kuilenburg AB, et al. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J. 2013;13(5):389–395.
   PubMed Web of Science ®Google Scholar
• EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. EMA./229267/2020. 2020. Available from: https://www.ema.europa.eu/en/documents/press-release/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine_en.pdf
   Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, Arain MA, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–359.
   PubMed Web of Science ®Google Scholar
• Lam SW, Guchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev. 2016;50:9–22.
   PubMed Web of Science ®Google Scholar